Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02221830 · ClinicalTrials.gov registry record · Early Phase 1

Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)

A Early Phase 1 study of Preeclampsia, sponsored by University of Colorado, Denver.

Completed
Registry status
Early Phase 1
Development phase
66
Enrollment target
1
Study location

NCT02221830 is a Early Phase 1 study of Preeclampsia that has completed, run by University of Colorado, Denver. The registered enrollment target is 66 participants, below the 1,280-participant average among 39 other Preeclampsia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02221830, a Early Phase 1 study of Preeclampsia, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Early Phase 1
Development phase
66 participants
Enrollment target
1
Study location

Study Summary

Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)

Conditions Studied

Preeclampsia

Interventions

  • DRUG Placebo
  • DRUG Oxytocin

Study Locations (1)

Colorado

  • University of Colorado Clinical and Translational Research Center - Aurora

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2015-02
Est. Completion 2019-07-17
Phase Early Phase 1

Sponsor

University of Colorado, Denver

1,283 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02221830

The ClinicalTrials.gov registry entry for NCT02221830 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,280-participant average among 39 other Preeclampsia trials with a reported enrollment target (95% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02221830 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT02221830 about?

NCT02221830 is a clinical study titled "Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)". Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)

What is the current status of trial NCT02221830?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 66 participants. The study started on 2015-02. Estimated completion is 2019-07-17.

What conditions does trial NCT02221830 study?

This clinical trial studies the following conditions: Preeclampsia.

What interventions are being tested in trial NCT02221830?

The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).

Who is sponsoring clinical trial NCT02221830?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02221830 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Preeclampsia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Preeclampsia

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.